Journal ArticleOPEN ACCESS

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate: An evidence-based case report and review of literature

Clinical Case Reports (2019) 7(8) 1585-1590
DOI: 10.1002/ccr3.2288
2Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration-resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.

Author supplied keywords

Cite

CITATION STYLE

APA

Yausep, O. E., Agarwal, R., Aulina, R., Wijaya, A. E., Amaia, I., Moekti, A. W., … Hamid, A. R. A. H. (2019). Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate: An evidence-based case report and review of literature. Clinical Case Reports, 7(8), 1585–1590. https://doi.org/10.1002/ccr3.2288

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free